- Home
- ABOS vs ARCT Comparison
ABOS vs ARCT Comparison
Compare ABOS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | ARCT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 163.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ABOS | ARCT |
|---|---|---|
| Price | $2.87 | $16.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.00 | ★ $24.11 |
| AVG Volume (30 Days) | 342.1K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.21 | $5.50 |
| 52 Week High | $3.60 | $24.14 |
Technical Indicators
Market Signals| Indicator | ABOS | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 65.93 |
| Support Level | $2.13 | $6.47 |
| Resistance Level | $3.02 | $17.75 |
| Average True Range (ATR) | 0.19 | 1.37 |
| MACD | -0.04 | -0.24 |
| Stochastic Oscillator | 33.33 | 58.75 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.